Timing of treatment of smoldering myeloma: early treatment

about

Timing of treatment of smoldering myeloma: early treatment

Item

http://www.wikidata.org/entity/Q59137899

description

scientific article published on 01 November 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Timing of treatment of smoldering myeloma: early treatment

@en

Timing of treatment of smoldering myeloma: early treatment

@nl

type

Item

label

Timing of treatment of smoldering myeloma: early treatment

@en

Timing of treatment of smoldering myeloma: early treatment

@nl

prefLabel

Timing of treatment of smoldering myeloma: early treatment

@en

Timing of treatment of smoldering myeloma: early treatment

@nl

P1476

Timing of treatment of smoldering myeloma: early treatment

@en

P2093

María-Victoria Mateos

http://www.w3.org/2001/XMLSchema#string

P2860

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.

P304

3045-3049

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOODADVANCES.2018021220

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Verónica González-Calle

María-Victoria Mateos

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30425068

http://www.w3.org/2001/XMLSchema#string

P932

6234377

http://www.w3.org/2001/XMLSchema#string